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SignallingThe pleiotropic pro-inﬂammatory cytokine tumour necrosis factor alpha (TNF) is synthesised as a transmembrane
protein that is subject to palmitoylation. In this study, the roles of this acylation on TNF-mediated biological effects
were investigated. We found that the lipid raft partitioning of TNF is regulated by its palmitoylation. Furthermore,
wedemonstrated that this palmitoylation process interfereswith the cleavage/degradation of TNF intracellular frag-
ments but is not involved in the regulation of its ectodomain shedding.Moreover, we found that the palmitoylation
of TNF hinders the binding of soluble TNF to TNFR1 and regulates the integration/retention of TNFR1 into lipid rafts.
Finally, we demonstrate that the transmembrane forms of wild-type and palmitoylation-defective TNF interact dif-
ferently with TNFR1 and regulate NFκB activity, Erk1/2 phosphorylation and interleukin-6 synthesis differently,
strongly suggesting that palmitoylation of TNF is involved in the regulation of TNFR1 signalling. An evidence for
the physiological intervention of this regulation is provided by the fact that, in macrophages, the binding of endog-
enous soluble TNF to TNFR1 is enhanced by inhibition of palmitoylation. Therefore, our data introduce the new con-
cept that palmitoylation of TNF is one of themeans bywhich TNF-producing cells regulate their sensitivity to soluble
TNF.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Tumour necrosis factor alpha (TNF) is a pro-inﬂammatory cytokine
that exhibits a wide range of biological effects. TNF is synthesised as a
type II transmembrane protein (tmTNF). Upon stimulation, the TNF
alpha-converting enzyme ADAM17 cleaves the extracellular domain of
tmTNF, which releases the soluble TNF (sTNF) [1]. The newly generated
membrane-bound moiety of TNF is further cleaved within its intra-
membrane region by signal peptide peptidase-like 2b (SPPL2b), leading
to the generation of an intracellular domain (ICD) of TNF [2].
Soluble TNF signals through two distinct cell surface receptors,
TNFR1 and TNFR2. Most of the biological activities of TNF are mediated
through TNFR1 [3]. Upon binding to TNFR1, the ligand-bound receptor
aggregates and serves as a scaffold to recruit adaptor proteins [4]. The
activated submembranous complex triggers cellular activation via
NFκB and mitogen-activated protein kinases or apoptosis via complex
internalisation and activation of apical caspases.eMédecine, 27 Bd JeanMoulin,
; fax: +33 4 91254336.
tti).
l rights reserved.In recent years, it has become clear that sTNF is not solely responsi-
ble for all of the effects of TNF. Indeed, tmTNF elicits biological activities,
some of which are similar to those of sTNF and some of which are
distinct [5–8]. These biological effects involve the binding of TNF to its
speciﬁc receptors and downstream signal transduction either by the
transmembrane receptors (forward signalling) or by tmTNF (reverse
signalling) [9,10]. Furthermore, the ICDmight possess biological effects;
its overexpression has been shown to stimulate the activity of the
interleukin-1β (IL1β) promoter and to trigger interleukin-12 (IL12)
expression [11,12]. Therefore, it is plausible that TNF-producing cells
are subject to the simultaneous actions of tmTNF, sTNF and ICD.
The diversity of TNF-mediated signalling responses is facilitated by
lipid rafts. The two TNF receptors are partially embedded in lipid rafts
[13–15], and the destruction of these membrane microdomains alters
the cellular response to TNF [16,17]. It has been proposed that depending
onwhether TNFR1 signalling emanates from inside or outside lipid rafts,
it can induce strong or weak NFκB activation, respectively (reviewed in
[18,19]). Furthermore, the dynamic distribution of speciﬁc transmem-
brane proteins between lipid raft and non-raft phases has been demon-
strated to inﬂuence the regulation of their functions [20]. This applies to
TNF signalling; upon sTNF binding, the TNF–TNFR1 complex translocates
into lipid rafts, where it is internalised and initiates proapoptotic signals
Table 1
release and cell surface expression of TNF.
sTNF released Cell surface tmTNF
Hela 3T3L1 Hela clones Hela clones
Control 6.38±0.6 nd 0.12±0.03 1±0.11
TNF 380±21 3.48±0.57 0.90±0.05 6.41±0.72
ΔpalTNF 378±30 3.28±0.70 0.98±0.09 6.34±0.61
Cells that transiently (Hela, 3T3L1) or stably (Hela clones) express TNF or ΔpalTNF and
their control were incubated for 14 h in fresh culture media. sTNF accumulated in the
media was measured by ELISA and expressed as pg/μg of total cellular protein (±s.d.).
Cell surface expression of tmTNF was measured by ﬂow cytometry and normalised to the
control situation as described in the Materials and methods section. nd = not detected.
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integrates signals emanating simultaneously from different membrane
domains.
Although its biological signiﬁcance remains unknown, a signiﬁcant
amount of tmTNF localises within lipid rafts [15,23,24]. Palmitoylation
of the juxtamembrane cytoplasmic Cys30 of tmTNF [25] was suggested
to be responsible for the targeting of TNF into lipid rafts, as a non-
palmitoylable mutant form of TNF is not integrated into these mem-
brane microdomains [24].
Our study aims to evaluate the impact of TNF palmitoylation on its
regulation and function. We found that this palmitoylation is necessary
for both the lipid raft partitioning of TNF and the processing of its cellu-
lar fragments but is dispensable for the shedding of its ectodomain.
Importantly, we demonstrated that palmitoylated TNF interferes with
the binding of sTNF to TNFR1 and regulates TNFR1 integration/retention
in lipid rafts, phenomena that involve a physical interaction between
TNFR1 and palmitoylated TNF. As a result, TNF palmitoylation contrib-
utes to the regulation of TNFR1 signalling.
2. Materials and methods
2.1. Reagents
The general metalloproteinase inhibitor GM6001, 2-bromohexa-
decanoic acid (bromopalmitate), phorbol 12-myristate 13-acetate
(PMA), methyl-β-cyclodextrin and anti-Flag M2 afﬁnity agarose
were from Sigma-Aldrich. The cleavable bifunctional crosslinker di-
methyl 3,3′-dithiobispropionimidate (DTBP) was from Pierce. The
signal peptide peptidase inhibitor (Z-LL)2-ketone and the MEK inhib-
itor PD098059 were from Calbiochem. Human recombinant soluble
TNF and mouse recombinant soluble TNF were from Peprotech. Anti
bodies against TNF (N-19), TNFR1 (H-5), actin (C-11), caveolin-1
(N-20), HA epitope (Y-11), Erk2 (D-2), p-Erk (E-4) and NFκB p65 (A)
were from Santa Cruz Biotechnology. Antibodies against ADAM17
(AB930; polyclonal; discontinued), TNF (clone 1825 for blocking and
clone 6401 for ﬂow cytometry) and TNFR1 (clone 16803 for blocking
and ﬂow cytometry) were from R&D Systems. The DYKDDDDK epitope
tag (Flag) polyclonal antibody (PA1-984B) was from Pierce. Antibodies
against IκBα (9242) and p-NFκB p65 (93H1) were from Cell Signaling
Technologies.
2.2. Expression vectors
Human TNF and TNFR1 expression vectorswere described previously
[26]. The non-palmitoylable form of TNF (ΔpalTNF) was generated by
substituting Cys30 with Ala (N-terminal amino acid = position 1).
A Flag tag (DYKDDDDK) was added at the N-terminal position of the
different forms of TNF. Expression vectors for active and inactive forms
of HA-tagged SPPL2b were described previously [27]. The mouse
ADAM17-expression vector was provided by J. Peschon [1].
2.3. Cell culture and transfection
Hela, 3T3L1, ADAM17-deﬁcient (ADAM17zn/zn) and RAW264.7 cell
lines were cultured as previously described [28–30]. Transient transfec-
tions were performed with Polyjet reagent (SignaGen Laboratories), as
speciﬁed by the manufacturer's protocols. For all cotransfections, an
empty plasmid was used to keep the amount of DNA constant. For
stable expression of TNF, Hela cells were transfected with linear vectors
using Polyjet reagent. Forty-eight hours after transfection, 1 mg/mL of
G418 sulphate was added, and the cells were subjected to a limiting
dilution procedure. Two independent clones expressing comparable
levels of TNF and ΔpalTNF at their surface and releasing comparable
levels of sTNF (Table 1) were chosen. These clones were then cultured
in the presence of 300 μg/mL of G418 sulphate. ICD was detectedusing the previously established and validated model of HEK 293 cells
overexpressing SPPL2b [31].
2.4. Cell surface binding and internalisation of sTNF
Hela cells were washedwith ice-cold PBS, washed twice for 2 min in
an acidic buffer (50 mM glycine pH 3, 100 mMNaCl), and then washed
again with PBS. Recombinant murine sTNF (100 ng/mL) was added to
the cells and incubated for 1 h on ice, and then the cellswere extensively
washed with PBS. To measure the cell surface binding of sTNF, the cells
were lysed at this stage using 1% Triton X 100 in PBS. For the measure-
ment of sTNF internalisation, the cells were incubated at 37 °C for 1 h,
washed twice with the acidic buffer and then lysed. The murine sTNF
contained in cell lysates was measured by ELISA and the results are
shown as the means±s.d. normalised to the control situation.
2.5. Isolation of lipid rafts
Low density detergent-resistant membrane domains, referred to
herein as lipid rafts, were isolated by sucrose density gradient centrifuga-
tion of cells treated with the non-ionic detergent Brij 98, as described
previously [15]. Brieﬂy, 5 to 10×106 cells were washed with ice-cold
PBS, harvested by scraping, collected by centrifugation, and resuspended
in 900 μL of “raft buffer” (20 mM Hepes, pH 7.4, 150 mM NaCl, 1 mM
EGTA, with protease, phosphatase and metalloproteinase inhibitors).
Lysis was performed by equilibrating the cell suspension at 37 °C,
followed by the addition of Brij 98 to a ﬁnal concentration of 1%. The
incubationwas carried out at 37 °C for 10 min. Onemillilitre of the lysate
was combinedwith an equal volume of 90% (w/v) sucrose, transferred to
12 mL ultracentrifuge tubes, overlaid with a discontinuous sucrose
gradient composed of 4 mL of 35% sucrose, and further overlaid with
2 mL of 5% sucrose. Separation of the low-density lipid rafts was
achieved by ultracentrifugation at 280,000 g in a swinging bucket rotor
for 18–22 h at 4 °C. Following ultracentrifugation, 0.5 mL fractions
were harvested from the top of the gradient.
2.6. Detection of TNF palmitoylation
Detection of TNF palmitoylation was performed by click chemistry
[32], in which, incorporated azido-palmitate was reacted with biotin-
alkyne (Life Technologies). Brieﬂy, Hela cells were washed twice
with serum free media and incubated for 12 h in the labelling media
containing 0.7% fatty-acid free BSA and 70 μM of azido-palmitate. Cells
werewashed and either lyzed directly or submitted to lipid raft isolation.
Pools of lipid raft and non-raft fractions containing comparable amounts
of TNF were collected. The protein content and composition of the pools
were equilibrated by adding a pool of non-raft fractions from control
cells to the pool of raft fractions from TNF expressing cells; reciprocally,
a pool of raft fractions from control cells was added to the pool of non-
raft fractions from TNF expressing cells. After chloroform/methanol pre-
cipitation, proteins were reacted by click chemistry with biotin-alkyne,
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teins were enriched by neutravidin-agarose (Thermo Pierce) binding
and analysed by western blot using TNF antibody (N-19).2.7. Immunoprecipitation
For immunoprecipitation of native ectopically expressed proteins,
cells were washed with PBS and then lysed in lysis buffer (50 mM
Hepes, pH 7.4, 5 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, 1% Triton
X 100 (v/v), protease and phosphatase inhibitors). Lysates were
preclariﬁed by centrifugation and incubated for 4 hwith FlagM2 afﬁnity
agarose. After incubation, the agarose was pelleted by centrifugation,
washed 3 times, boiled in SDS-PAGE sample buffer and submitted to
immunoblot analysis. For immunoprecipitation of crosslinked ectopically
expressed proteins, the cells were washed with PBS, incubated for
30 min at room temperaturewith the crosslinker DTBP (5 mM), washed
twice with 50 mM Tris HCl, pH 7.4, and then lysed with RIPA buffer
(50 mM Tris–HCl, pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 0.1%
SDS, 150 mM NaCl). Lysates were treated for immunoprecipitation as
described above.2.8. Puriﬁcation of cell surface protein
The cell surface protein isolation kit from Pierce that uses the cell-
impermeable, cleavable biotinylation reagent, sulfo-NHS-SS-biotin, was
used according to the manufacturer's protocols. Equal amounts of total
proteins from each sample were puriﬁed on NeutrAvidin agarose resin.2.9. Immunoblot
Equal amounts of protein from each cell lysate were resolved
under denaturing and reducing conditions on 4–12% NuPAGE gels
(Life Technologies) and then transferred to polyvinylidene ﬂuoride
membranes (Millipore). Immunoreactive proteins were revealed
by enhanced chemiluminescence with ECL (Perkin-Elmer). Images
were captured using a CCD camera (ImageQuant™ LAS 4000 system;
GE Healthcare), and the intensity of the bands was evaluated by the
image analysis software ImageQuant™ TL.2.10. ELISA assays
The human TNF and interleukin-6 (IL6) ELISA kits were from Life
Technologies and eBioscience, respectively. The human and mouse
TNFR1 TNF ELISA kits were from R&D Systems. The TNFR1–TNF
heterodimer immunoassay was made by combining the capture anti-
body from the mouse TNFR1 ELISA kit and the detection antibody from
the mouse TNF ELISA kit. The phospho-Erk1/2 ELISA kit was from
RayBiotech.2.11. Immunoﬂuorescence microscopy
Cells cultured on microscopy chamber slides (Labtek) were
treated for immunoﬂuorescence detection of Flag-tagged TNF.
Brieﬂy, cells were washed, ﬁxed on ice with 4% paraformaldehyde
for 10 min, permeabilised with 0.2% Triton X 100 in PBS and
saturated for non-speciﬁc binding with 3% BSA for 30 min. After 1 h of
incubation with the anti-Flag antibody, cells were incubated with a
secondary antibody coupled to Alexa Fluor 546. Cells were mounted
in a DAPI-containing medium and visualised using a ﬂuorescence
microscope (Leica DMRB). Images were captured using a camera
(ProgRes CFcool; Jenoptik, Germany) and ProgRes Capture Pro software
(version 2.6). Images were prepared for presentation using ImageJ
software with minimal processing.2.12. Flow cytometry analysis
Cells were washed with PBS and subject or not to two washes of
2 min with the acidic buffer, followed by a subsequent PBS wash,
and detached by Accutase treatment. Surface expression of tmTNF
and TNFR1 was determined by ﬂow cytometric analyses using
PE-conjugated (clone 6401) and APC-conjugated (clone 16803) anti-
bodies, respectively. Labelled cells were analysed on the Accuri C6
ﬂow cytometer. The means±s.d. of ﬂuorescence intensities were
recorded and for ease of reading, values were corrected for the
value obtained with an isotype control and normalised to the control
situations.
2.13. Gene reporter experiments/luciferase assay
Cells were cotransfected with an NFκB-ﬁreﬂy luciferase reporter
(Panomics; Fremont, CA, USA) and a renilla luciferase control (PGL4
sv40 from Promega) vector. Fireﬂy and renilla luciferase activities
weremeasured using a luminometer (Victor X; Perkin Elmer). The tran-
scriptional activity of NFκB is shown as the ratio of the arbitrary units of
luminescence of ﬁreﬂy versus renilla luciferase and normalised to
controls.
2.14. Real time PCR analysis
Total RNAwas extracted using the PureLink RNAMini Kit (Life Tech-
nologies). RT-PCR was performed using a 7300 real-time PCR system
(Applied Biosystems) using the Eva Green MasterMix (Euromedex).
The relative levels of the different mRNAs were measured with the
comparative CT method (2−(ΔΔCT)). Acidic ribosomal phosphoprotein
P0 (36B4) was used as an internal housekeeping control transcript.
Primer sequences are provided in Supplementary Table S1.
2.15. Caspase 8 assay
Caspase 8 activity was measured with a colorimetric assay
kit according to the manufacturer's protocols (PromoKine). The
assay is based on spectrophotometric detection of the chromophore
p-nitroanilide (pNA) after cleavage from the labelled substrate
IETD-pNA. The pNA light emission was quantiﬁed using a microtiter
plate reader at 405 nm.
2.16. Statistical analyses
All experiments were performed in triplicates and repeated, at least,
three times. All data are expressed as the mean±s.d. Treatments were
compared with their respective controls, and signiﬁcant differences
among the groups were determined using the unpaired Student's
t-test. A value of pb0.05 was considered statistically signiﬁcant. Results
obtainedwith the independent Hela cloneswere very close and for ease
of reading, they were combined in the statistical analysis.
3. Results
3.1. Palmitoylation of TNF promotes its lipid raft integration
A long period of accumulation was necessary to measure trace
amounts of sTNF in culture media of mock transfected Hela cells
(Table 1), whereas tmTNF was undetectable in their lysates (Fig. 1D).
Overexpression of TNF greatly increased sTNF levels andwasmandatory
for the detection of tmTNF (Table 1 and Fig. 1D).
The small amounts of tmTNF detected in lipid rafts of TNF
overexpresing Hela cells were signiﬁcantly reduced by a treatment
with the general palmitoylation inhibitor bromopalmitate (Fig. 1A),
which did not notably affect the distribution of the lipid raft marker
caveolin-1. This result implies that the incorporation of TNF into
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tmTNF was preferentially detected inside lipid rafts (Fig. 1B). This result
highlights the importance of TNF palmitoylation in the regulation of
its lipid raft partitioning. Moreover, a palmitoylation-defective form
of TNF (ΔpalTNF) (Fig. 1B) was less integrated into lipid rafts than
wild-type TNF (Fig. 1C, D), proving that the localisation of TNF in lipid
rafts requires its speciﬁc palmitoylation. Despite this difference in lipid
raft integration, the cell surface expression (Fig. 1E and Table 1) and
the general cellular localisation of overexpressed TNF and ΔpalTNF
(Fig. 1F) were similar.
3.2. Palmitoylation of TNF is not essential for the cleavage of its
extracellular domain
We analysed whether TNF palmitoylation participated in the
regulation of its ectodomain shedding.
ADAM17-deﬁcient (ADAM17Zn/Zn) mouse ﬁbroblasts transiently
overexpressing TNF or ΔpalTNF released comparable levels of sTNF,
which were increased to similar extents by the simultaneous over-
expression of ADAM17 and by PMA treatment (Fig. 2A). Similarly,
overexpression of TNF orΔpalTNF inHela or 3T3L1 cells led to the release
of comparable amounts of sTNF (Fig. 2B and Table 1). These results
indicate that the palmitoylation of TNF is minimally or not involved in
the regulation of ADAM-17-dependent cleavage of its ectodomain.Fig. 1. Palmitoylation of TNF contributes to its lipid raft integration. (A) Hela cells stably express
lipid raft isolation as indicated in the Materials and methods section. TNF contained in the frac
was measured by ELISA and expressed as the percentage of the total levels present in the gra
(B) Palmitoylated TNF (palm TNF) was measured as described in the Materials and methods s
of Hela cells expressing TNF orΔpalTNF. (C) Hela cells transfectedwith TNF orΔpalTNF were tr
density gradient. Then lipid raft fractions (3–7) and non-raft fractions (8–15)were pooled, conc
A and C are positioned above lipid raft fractions and show the % of TNF contained in those fractio
ΔpalTNF and ADAM17. Mature and pro-forms of ADAM17 are indicated by the black and whit
were detected by immunocytochemistry using an anti-Flag antibody and epiﬂuorescence mic
fractionation; c: cells transfected with empty plasmid.However, the shedding of TNF and ΔpalTNF was comparably stimulated
by disruption of lipid rafts (Fig. 2B) suggesting that the integrity of lipid
rafts is required for the proper regulation of TNF shedding.
3.3. Palmitoylation of TNF is required for the correct processing of its
intracellular fragments
Notably, even if the levels of full-length TNF and ΔpalTNF over-
expressed in ADAM17Zn/Zn, Hela and 3T3L1 cells were comparable, the
N-terminal fragment of TNF (NTF), which remains membrane-
anchored after the cleavage of the ectodomain, was more present in
TNF-overexpressing cells (Fig. 3A,B). In ADAM17Zn/Zn cells, stimulation
of TNF shedding by overexpression of ADAM17 (Fig. 2A) reduced
the levels of full-length tmTNF and increased the levels of its NTF
(Fig. 3A). As expected, activation of ADAM17-dependent shedding of
TNF by a short exposure to PMA (Fig. 2A), reduced the levels of
full-length TNF and increased the levels of its NTF (Fig. 3A, B). In con-
trast, the NTF of the ΔpalTNF was almost undetectable under similar
conditions. Furthermore, we showed that the amount of NTF derived
from full-length TNF was reduced by bromopalmitate, whereas the
amount of NTF derived from ΔpalTNF was not altered by this treatment
(Fig. 3C). However, bromopalmitate treatment similarly reduced the
shedding of TNF and ΔpalTNF (Fig. 3D). Altogether, these data imply
that palmitoylation of TNF stabilises its NTF.ing TNFwere treated or not for 14 hwith 100 μMbromopalmitate (Bp) then submitted to
tions of the sucrose density gradient (numbered according to increasing sucrose density)
dient. TNF and the lipid raft marker caveolin-1 (cav) were also detected by western blot.
ection in lipid raft and non raft fractions of Hela cells stably expressing TNF and in lysates
eated for lipid raft isolation and TNFwasmeasured by ELISA in the fractions of the sucrose
entrated and TNF and caveolin-1 (cav)were detected by immunoblot (D). Insets in panels
ns (p values are indicated). (E) Immunoblot detection of total and cell surface exposed TNF,
e arrowheads, respectively. (F) Flag-tagged TNF and ΔpalTNF overexpressed in Hela cells
roscopy (red); nuclei were stained with DAPI (blue); bars = 10 μm. i: cell lysate before
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protease SPPL2b, whereupon the ICD is released. As expected, the
overexpression of active SPPL2b reduced the levels of NTF detected
(Fig. 4A and Fig. S1). However, treatment of cells overexpressing
ΔpalTNF with a pharmacological inhibitor of signal peptide peptidase
did not restore the levels of NTF comparable to those observed in cells
overexpressing TNF (Fig. 4B). Moreover, the increased levels of NTF
induced by long-term inhibition of signal peptide peptidases were
consistently greater in cells overexpressing TNF (+40%±6%) than
in those overexpressing ΔpalTNF (+13%±7%). Furthermore, ICD was
not detectable in ΔpalTNF-overexpressing cells (Fig. 4C and Fig. S1).
These results indicate that the NTF derived from ΔpalTNF ectodomain
shedding is rapidly degraded and suggest that its degradation is not
only attributed to proteolysis by SPPL2b. We further evaluated the
stability of the NTF generated from the two forms of TNF. For this pur-
pose, we blocked NTF generation by inhibiting TNF ectodomain shed-
ding (Fig. 4D) using a metalloproteinase inhibitor active on ADAM17
(GM6001), and we analysed NTF levels after 5 h of inhibitor treatment.
The NTF generated from TNF was relatively stable over this short period
of time (Fig. 4E) and the inhibition of signal peptide peptidases did
not elicit any apparent effects. Conversely, the inhibition of ΔpalTNF
ectodomain shedding was accompanied by a reduction in the levels
of its NTF (−30%±7%), indicating its active degradation. This degra-
dation was not blocked by the inhibition of signal peptide peptidases
(surprisingly, it was even slightly increased). Taken together, these
results highlight that the palmitoylation of TNF is essential for the
stabilisation of its NTF and for its subsequent, efﬁcient cleavage by
SPPL2b.Fig. 2. Palmitoylation of TNF is not essential for its extracellular shedding. Soluble TNF
(sTNF) was measured by ELISA in the culture media of (A) ADAM17Zn/Zn cells
transfected with TNF or ΔpalTNF in association or not with ADAM17 then stimulated
or not for 30 min with 100 nM of PMA and (B) Hela cells transfected with TNF or
ΔpalTNF incubated for 30 min with 1% of methyl-β-cyclodextrin (CD). Values are
shown in pg/μg of protein contained in the cell lysates.3.4. The cleavage of NTF by SPPL2b occurs preferentially in lipid rafts
As previously described [33], we found that a large proportion of
overexpressed SPPL2b localised inside lipid rafts (Fig. S2A) and we
analysed whether the SPPL2b-mediated cleavage of NTF occurs in
lipid raft. Inhibition of signal peptide peptidase activity efﬁciently
increased the levels of NTF present within the lipid rafts andmodestly
increased the levels of NTF outside the lipid rafts (Fig. S2B). These
results indicate that SPPL2b more efﬁciently cleaves NTF that is
partitioned inside the lipid rafts.
3.5. Palmitoylation of TNF modulates TNF responses
Since palmitoylation of TNF regulates several aspects of its biology
(lipid raft partitioning, degradation and generation of its intracellular
fragments), we analysed whether this acylation could also change its
biological activity.
3.5.1. The NFκB target genes
We investigated whether wild type and palmitoylation-deﬁcient
forms of TNF elicited differential effects on cellular responses triggered
by bioactive TNF. For this purpose, we ﬁrst analysed the expression of
several TNF target genes (plasminogen activator inhibitor-1, IκB, IL6,
TNF and IL1β) in Hela cells that transiently overexpressed TNF or
ΔpalTNF. This model was used to highlight the strong effects of
tmTNF (as compared to sTNF). Indeed, only a subset of cells (30 to
40%) overexpressed tmTNF and produced signiﬁcant levels of sTNF
(Table 1), which acts on all the cells. Among TNF target genes whose
expression was measured, only IL6 was repeatedly and signiﬁcantly
expressed to higher levels in Hela cells that transiently overexpressed
ΔpalTNF compared to TNF-overexpressing cells (Fig. S3A). However,
although signiﬁcant, this difference of expression was rather low,
therefore this result was veriﬁed and reinforced in stably transfected
Hela cells that are overexpressing comparable levels of transmembrane
TNF and ΔpalTNF at their surface and releasing comparable levels of
sTNF (Table 1); ΔpalTNF expressing cells synthesised more IL6 than
control and TNF-expressing cells (Fig. 5A, B). Consistently, IL6 mRNA
levels were increased in mouse ﬁbroblasts by 64% and 31% by the
transient overexpression of ΔpalTNF and TNF, respectively (Fig. S3B).
Stimulation with sTNF more efﬁciently increased IL6 synthesis in
control cells compared to Hela cells that expressed TNF or ΔpalTNF
(Fig. 5A, B).
The overexpression of the ICD of TNF in Hela cells has been reported
to increase IL1β promoter activity [11]. As TNF andΔpalTNF result in the
production of signiﬁcantly different levels of ICD (Fig. 4C), we analysed
how these two forms of TNF might regulate IL1β expression. Over-
expression of TNF and ΔpalTNF similarly increased the expression
of IL1β, which was reduced by the addition of a TNF-blocking antibody
but not by the inhibition of signal peptide peptidase activity (Fig. S3A).
These results indicate that the palmitoylation of TNF is likely not
involved in the regulation of IL1β expression and that IL1β expression
is principally regulated by the bioactive TNF and minimally by the ICD.
3.5.2. The NFκB signalling pathway
To better understand the disparity in IL6 expression levels, we
analysed the impact of TNF and ΔpalTNF on NFκB signalling. The stable
expression of TNF and ΔpalTNF in Hela cells decreased the levels of IκB
and increased the phosphorylation and the nuclear levels of NFκB
(Fig. S4A). A short stimulation with sTNF strongly increased NFκB
phosphorylation and decreased IκB levels in control cells but did
not signiﬁcantly elicit such effects in TNF- or ΔpalTNF-expressing
cells. These results indicate that TNF expression interferes with the
cellular response to sTNF. Quantitative analysis revealed that ΔpalTNF
expression was more effective than TNF expression in increasing
NFκB activity (+86% and +48%, respectively, compared to control
cells) (Fig. 5C). Furthermore, the increased NFκB activity triggered by
Fig. 3. Palmitoylation of TNF is required for the correct processing of its cellular fragments. The N-terminus of TNFwas detected by immunoblot analysis (using the anti-Flag antibody) in
lysates of (A) ADAM17Zn/Zn cells transfected with Flag-tagged TNF or ΔpalTNF in association or not with ADAM17 then stimulated with PMA, (B) Hela and 3T3L1 cells transfected with
Flag-tagged TNF orΔpalTNF then stimulatedwith PMA, (C) Hela cells transfected as in (B) and incubated for 14 hwith the indicated concentrations of bromopalmitate (Bp) (upper panel:
short exposure; lower panel: long exposure). (D) Western blot detection of sTNF accumulated in the media of Hela cells overexpressing TNF and ΔpalTNF treated or not with
bromopalmitate (BP; 100 μM for 14 h). TNF indicates full-length tmTNF; NTF indicates tmTNF fragment (generated by the ectodomain cleavage of TNF). Mature and pro-forms of
ADAM17 are indicated by the black and white arrowheads, respectively.
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TNF-expressing cells and non-existent in ΔpalTNF-expressing cells. Sim-
ilarly, the transient overexpression of human TNF andΔpalTNF inmouse
ﬁbroblasts reduced IκB levels and increased NFκB phosphorylation
(Fig. S4B). Luciferase reporter experiments revealed that TNF and
ΔpalTNF overexpression increasedNFκB activity by 23% and 55%, respec-
tively, compared to control cells (Fig. S4C). As forHela cells, the increased
NFκB activity triggered by sTNF treatmentwas lowbut signiﬁcant in con-
trol cells (+27%),marginal in TNF-overexpressing cells andnon-existent
in ΔpalTNF-overexpressing cells.3.5.3. The Erk1/2 signalling pathway
TNF activates the Erk1/2 signalling pathway [16,34], and the inhibi-
tion of Erk1/2 was sufﬁcient to reduce the stimulatory effect of sTNF
on IL6 expression (Fig. S3C). Thus, we analysed the effects of TNF and
ΔpalTNF expression on Erk1/2 phosphorylation. Stimulation of control
Hela cells with sTNF triggered a rapid increase in Erk1/2 phosphoryla-
tion, which persisted for at least 20 min (Fig. 5D). This pattern of phos-
phorylation was not signiﬁcantly different from that observed in TNF
transiently overexpressing Hela cells. The basal level of Erk1/2 phos-
phorylation in ΔpalTNF-expressing Hela cells was more than twice
that measured in control and TNF-expressing cells, and furthermore,
it was not stimulated by sTNF treatment. Western blot analysis
suggested that Erk2 was primarily responsible for the measurable
increase in Erk1/2 phosphorylation (Fig. 5E). An elevated level of Erk2
phosphorylationwas also observed inmurineﬁbroblasts that transiently
overexpressed ΔpalTNF (Fig. S4D).
Taken together, these data demonstrate that TNF and ΔpalTNF
differently regulate NFκB and Erk1/2 signalling, which could explain
their differential ability to stimulate IL6 synthesis.3.6. Palmitoylation of TNF modulates the binding of sTNF to TNFR1
TNFR1 represents the vastmajority of TNFRs inHela cells [35] andwe
veriﬁed that TNFR2 expression was not altered by TNF overexpression
(Fig. S5A). Importantly, TNFR1 is responsible for the TNF-dependent
õactivation of NFκB, Erk1/2 pathways and IL6 synthesis [16,34] and
human TNF exclusively signals through TNFR1 in mouse cells [36].
These observations support the possible involvement of TNFR1 in the
differential regulation of NFκB, Erk1/2 and IL6 induced by TNF and
ΔpalTNF.
Thus, we evaluated the binding of sTNF to TNFR1 in TNF- and
ΔpalTNF-expressing cells. The ability of our assay to measure the
binding of sTNF to TNFR1 was validated by the observation that the
cell surface binding of sTNF was increased by the overexpression of
TNFR1 and reduced by the addition of a TNFR1-blocking antibody
(Fig. 6A). TNF-expressing cells bound less sTNF than control and
ΔpalTNF-expressing cells (Fig. 6A, B). These results indicate that TNF
palmitoylation is involved in the control of sTNF binding to the cell
surface. However, after an acid wash, to remove any receptor-bound
ligand, TNF- and ΔpalTNF-expressing cells bound similar levels of
sTNF (Fig. 6B), suggesting that the binding of sTNF to TNFR1 is speciﬁ-
cally impaired in TNF-expressing cells. Unexpectedly, this binding was
similar to that obtained with control cells that expressed more TNFR1
at their surface (Fig. S5B). Although the speciﬁc role of palmitoylation
of endogenous TNF cannot be analysed in cells that express TNF
physiologically, we nevertheless determined whether binding of
sTNF to TNFR1 was effectively regulated by a palmitoylation process.
RAW264.7 mouse macrophages treated with PMA (to increase TNF
synthesis) and with an inhibitor of ADAM17 (to reduce TNF release)
were incubated or not with bromopalmitate. Bromopalmitate treat-
ment did not change the amount of cellular TNFR1 and TNF (Fig. 6C)
Fig. 4. NTF derived from ΔpalTNF undergoes SPPL2b-independent degradation. (A) Hela cells were transfected with Flag-tagged TNF or ΔpalTNF associated with inactive (−) or active
(+) forms of SPPL2b. (B) Hela cells were transfected with Flag-tagged TNF or ΔpalTNF and treated for 14 h with 20 μM (Z-LL)2-ketone (ZLL). (C) HEK 293 cells stably expressing active
SPPL2bwere transfected as in (B). The entire immunoblot analysis is shown in Fig. S1. (D) Hela cells transiently transfectedwith TNF orΔpalTNFwere treated or not with 10 μMGM6001
(GM) for 5 h. The accumulation of sTNF in the culture media wasmeasured by ELISA. Values are shown in pg/μg of protein in the cell lysates. (E) Hela cells were transfected as in (B) and
treated for 5 hwith 10 μMGM6001 (GM) orwith GM+ZLL. TNFwas detected as described in Fig. 3. Upper panels: short exposure; lower panels: long exposure. ICD indicates intracellular
domain of TNF generated by the action of SPPL2b. *Signiﬁcant versus the situation without GM6001 (pb0.006).
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endogenous sTNF was bound at the cell surface after bromopalmitate
treatment (Fig. 6E). Using a home-made TNFR1–TNF heterodimer im-
munoassaywe demonstrated that bromopalmitate treatment increased
the amount of TNF bound to cellular TNFR1 (Fig. 6F). These results argue
in favour of the role of a palmitoylation process in the regulation of sTNF
binding to the TNFR1 of cells expressing TNF physiologically.
3.7. Palmitoylation of TNF alters its interaction with TNFR1
Lipid rafts from control and TNF-expressing cells contained more
TNFR1 than those from ΔpalTNF-expressing cells (Fig. 7A, B), indicating
that the palmitoylation of TNF is involved in the regulation of the
partitioning of TNFR1 in lipid rafts. The difference in the levels of
TNFR1 in lipid rafts cannot be explained by its altered internalisation
(Fig. S6A) or shedding (Fig. S6B), as both events were similarly reduced
in TNF- and ΔpalTNF-overexpressing cells compared to control cells.
Moreover, TNFR1 was more efﬁciently coimmunoprecipitated with
full-length TNF thanwith ΔpalTNF (Fig. 7C, D). This result was observed
with both non-crosslinked proteins obtained from the lysis of the cells
using a mild, non-ionic detergent (Fig. 7C), as well as crosslinked
proteins obtained from an aggressive cell lysis (Fig. 7D). These results
suggest that TNFR1 interacts more efﬁciently with TNF than with
ΔpalTNF and that this interaction occurs in lipid rafts.
3.8. Palmitoylation of TNF does not modify Caspase 8 activation
TNFR1-dependent apoptosis is initiated by the activation of the
apical Caspase 8 [37,38]. However, we did not observe any difference
in Caspase 8 activity in cells expressing TNF or ΔpalTNF (Fig. S7),suggesting that certain aspects of TNFR1 signalling are not altered
by TNF palmitoylation.
4. Discussion
Palmitoylation of TNF was ﬁrst described more than ten years ago
[25]. However, the functional role of this particular acylation in TNF
biology and function was unknown. As a reversible lipid modiﬁcation,
cysteine palmitoylation is considered a dynamic lipid raft-targeting
mechanism for several transmembrane proteins [39]. Our results
demonstrate that the palmitoylation of TNF largely contributes to its
recruitment to lipid rafts without interfering with its intracellular
localisation or its cell surface expression. However, a small proportion
of palmitoylated TNF was also detected outside lipid rafts. We
previously reported that the mature form of ADAM17 is present both
inside and outside of lipid rafts and that its inhibition resulted in
increased TNF levels within lipid rafts [15]. This led to the hypothesis
that the extracellular domain of TNF is preferentially cleaved by
ADAM17 in these membrane microdomains. However, our current
results suggest that the role of lipid rafts in the regulation of the TNF
ectodomain shedding is more complex than originally anticipated, as
bothwild-type and palmitoylation-deﬁcient TNF (ΔpalTNF) are similarly
cleaved by ADAM17. Furthermore, we and others have proposed that
lipid raft disruption increased ADAM17 substrate shedding by allowing
their cleavage outside lipid rafts [15,40]. As wild-type TNF and ΔpalTNF
are mostly contained outside lipid rafts, it is therefore not surprising
that disruption of lipid rafts increases their release.
The palmitoylation of TNF is involved in the control of the intracellular
degradation of the transmembrane moiety generated by its ectodomain
shedding (i.e., NTF). Indeed, the NTF derived from TNF is relatively stable
Fig. 5. TNFR1 signalling is differentially altered by TNF andΔpalTNF. Stably transformed Hela cells were treated or not for 14 hwith sTNF (50 ng/mL), IL6mRNA levelsweremeasured by
RT-PCR (A) and the accumulation of IL6 protein in the culture media wasmeasured by ELISA (B). Values are shown as pg/μg of protein in the cell lysate. (C) Stably transformed Hela cells
were transfectedwith NFκB luciferase reporter, stimulated or not with sTNF, and NFκB activation wasmeasured as described in theMaterials andmethods section. The results are shown
as the ratio of ﬁreﬂy luciferase activity/renilla luciferase activity and normalised to the controls. (D) Phosphorylated and total Erk1/2 were measured by ELISA in the total lysates of Hela
cells that stably expressed the empty vector (c), TNF or ΔpalTNF and that were stimulated for the indicated periods of time with sTNF (50 ng/mL). The results show pErk1/2 signal
(OD 450 nm) normalised to the total Erk1/2 signal. (E) immunoblot of total Erk2 and phosphorylated Erk1/2. a — signiﬁcant versus cells transfected with empty vector (c) without
sTNF treatment (pb0.03); b — signiﬁcant versus cells overexpressing TNF without sTNF treatment (pb0.02).
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N-terminal fragment of TNF (ICD). The NTF generated by the ectodomain
shedding of ΔpalTNF is unstable (independent of the action of SPPL2b),
consequently impairing the detection of its derived ICD. However, this
NTF is nonetheless a substrate for SPPL2b because its levels are reduced
upon SPPL2b overexpression and are stabilised by treatmentwith a phar-
macological inhibitor of signal peptide peptidases. Thus, the increased
degradation of the ICD derived from ΔpalTNF cannot be excluded as a
possible explanation for the lack of its detection. Notably, the increased
levels of NTF derived from TNF processing induced by the pharmacolog-
ical inhibition of signal peptide peptidases are modest compared to the
dramatic loss of NTF resulting from SPPL2b overexpression. These data
suggest that in our cell model, NTF is not efﬁciently cleaved by SPPL2b.
Consistent with previous studies, we report that SPPL2b is contained
predominantly in lipid rafts [33]. The colocalisation of TNF and SPPL2b
in lipid rafts might explain why the NTF derived from TNF is a better
substrate for SPPL2b than the NTF derived fromΔpalTNF, which is largely
excluded from lipid rafts. The use of different inhibitors of intracellular
proteolytic systems did not enable us to identify the system responsible
for the accelerated degradation of NTF in cells that overexpressed
ΔpalTNF. Similar technical difﬁculties were reported previously in a
study of accelerated degradation of the non-palmitoylated form of the
C-terminal fragment of betacellulin (a γ-secretase substrate) [41]. The
NTF generated by TNF ectodomain shedding is detected in ADAM17-
deﬁcient cells, indicating that an ADAM17-independent cleavage of TNF
occurs in these cells, which is also illustrated by their ability to release
sTNF. However, the re-expression of ADAM17 reduces the levels of
full-length TNF, increasing the levels of NTF and proving that ADAM17
activity participates in the production of the NTF.
ICD overexpression was shown to stimulate the activity of the IL1β
promoter in Hela cells and to trigger IL12 expression in activated
human dendritic cells [11,12]. However, despite the fact that TNF
and ΔpalTNF lead to the production of signiﬁcantly different amounts
of ICD they similarly increase IL1β mRNA levels (the expression ofIL12 analysed by RT-PCR was below the detection limit), an effect
that is predominantly attributed to the bioactivity of TNF. The tran-
scriptional changes induced by the ICD generated from NTF cleavage
warrant further investigation, as they might provide evidence for
potential speciﬁc effects of TNF and ΔpalTNF.
Expression of TNFR1 at the surface of endothelial cells was shown
to be down-regulated by treatment with sTNF [42]. Furthermore,
overexpression of a non-secretable tmTNF mutein in L929 cells
resulted in a total TNFR1 down-modulation and induction of TNF
unresponsiveness [43], while in Hela cells, overexpression of a non-
secretable tmTNF did not signiﬁcantly affect TNFR1 surface expres-
sion [44]. In our Hela cell models, the chronic expression of TNF and
ΔpalTNF merely halves the total and cell surface levels of TNFR1.
This reduction of TNFR1 expression is likely not attributed to its
shedding or internalisation (as both were reduced). Interestingly,
the difference in TNFR1 expression at the surface of control and
TNF-expressing cells is not reﬂected by a difference in the binding of
sTNF to TNFR1, suggesting that sTNF binding to TNFR1 is not only
regulated by the levels of TNFR1 expressed at the cell surface. However,
although TNF and ΔpalTNF-expressing cells expose similar amounts
of tmTNF at their surface and release comparable levels of sTNF, our
results indicate that less sTNF binds to TNFR1 at the surface of TNF-
expressing cells compared to ΔpalTNF-expressing cells (and control
cells). An impediment of sTNF binding at the surface of Hela cells that
overexpress a non-secretable tmTNF was previously reported and
explained by the formation of a complex between tmTNF and TNFR1
[44]. Our results are consistent with this explanation; indeedwe showed
that TNFR1 is more efﬁciently coimmunoprecipitated with tmTNF
than with tmΔpalTNF. As the lipid rafts from TNF-overexpressing cells
contain more TNFR1 than those from ΔpalTNF-overexpressing cells, the
coimmunoprecipitation of TNF and TNFR1 might be explained either
by an interaction between the two proteins or by the precipitation of
TNFwith all or part of the lipid raft domains containing TNFR1. However,
after crosslinking and lipid raft lysis, TNFR1 is still more efﬁciently
Fig. 6. Palmitoylation of TNF modulates the binding of sTNF to TNFR1. sTNF binding assays
were performed as described in the Materials and methods section on (A) Hela cells tran-
siently transfected with TNF, ΔpalTNF or TNFR1 and incubated for 1 h with 10 μg/mL of
TNFR1-blocking antibody (αR1); (B) control and stably TNF- or ΔpalTNF-expressing Hela
cells (untreated or acid-washed). Endogenous TNF and TNFR1 were measured by ELISA in
the lysates (C) and culture media (D) of RAW264.7 cells treated for 18 h with PMA
(20 nM) and TMI-1 (5 μM) in absence or presence of bromopalmitate (Bp; 100 μM).
Endogenous sTNF bound at the surface of RAW264.7 cells was measured after its release
by the acid wash of the cells (E). Endogenous sTNF bound to RAW264.7 TNFR1 was mea-
sured in cell lysate using ahome-madeheterodimer immunoassaydescribed in theMaterials
and methods section (F). a — signiﬁcant versus control (c) (pb0.02).
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a closer proximity between TNF and TNFR1 than between ΔpalTNF
and TNFR1. This result is consistent with a favoured interaction between
TNF and TNFR1, which does not preclude the possibility that this interac-
tion occurs in lipid rafts. An indication of the physiological involvement
of TNF palmitoylation in the regulation of its interaction with TNFR1
is provided by the observation that global inhibition of palmitoylation
by treating macrophages (that physiologically express TNF) with
bromopalmitate increases the binding of sTNF to TNFR1. Incidentally, it
should be noticed that bromopalmitate reduces the shedding of TNF as
well as that of the non-palmitoylated proteins ΔpalTNF and TNFR1
[45]; this highlights the limitations of using bromopalmitate to unambig-
uously conclude on the role of the palmitoylation of a speciﬁc protein
and emphasizes the need for approaches involving the expression of
palmitoylation deﬁcient form of the studied protein.
TNFR1 has been detected in lipid rafts during basal condi-
tions [13,14,42], and the engagement of TNFR1 with sTNF has been
shown to lead to a transient increase (within minutes) [14] or to a
net decrease [42] in the levels of TNFR1 in lipid rafts. Our models
of TNF-producing cells are chronically exposed to the released
sTNF, and we assessed the steady state levels of TNFR1 in lipidrafts. Control and TNF-expressing cells contain comparable levels
of TNFR1 in lipid rafts, which weakens the hypothesis that TNFR1
is driven into lipid rafts by a potential interaction with tmTNF. As
TNFR1 and tmΔpalTNF do not exhibit a strong interaction, the low
levels of TNFR1 in lipid rafts of tmΔpalTNF-expressing cells cannot
be explained by its retention outside lipid rafts due to an interaction
with tmΔpalTNF. It is conceivable that tmΔpalTNF, which is sparsely
represented in lipid rafts, interacts poorly with TNFR1 and does
not impair the binding of sTNF to the receptor. As a consequence,
the sTNF/TNFR1 complex is normally downregulated in lipid rafts.
Conversely, palmitoylated tmTNF interacts with TNFR1 in lipid
rafts, which blocks the binding of sTNF to a subset of receptors;
the palmitoylated tmTNF/TNFR1 complex is not downregulated.
The low level of TNFR1 blocked by tmTNF in lipid rafts compared
to the total levels of TNFR1 might explain why we did not observe
decreased internalisation of sTNF in TNF-overexpressing cells
compared to those expressing ΔpalTNF. In agreement with such a
difference in the biology of TNFR1 in TNF- and ΔpalTNF-expressing
cells, we showed that some aspects of post-TNFR1 signalling
are differentially affected. Indeed, basal NFκB activity and Erk1/2
phosphorylation are higher in ΔpalTNF-expressing cells than in
control and TNF-expressing cells. Furthermore, stimulation with
sTNF increased NFκB activity and Erk1/2 phosphorylation only
in control and TNF-expressing cells but not in cells expressing
ΔpalTNF. Elevated NFκB activity and Erk1/2 phosphorylation in
ΔpalTNF expressing cells might explain the lack of responsiveness
of these cells to sTNF. These alterations in the signalling down-
stream of TNFR1 affect the cellular response to TNF, which is illus-
trated by differential expression levels of IL6 (an NFκB-target
gene) in TNF- and ΔpalTNF-expressing cells. Importantly, constitu-
tive activation of NFkB and IL6 production associated with a reduced
response to sTNF was already described in Hela cells overexpressing
non-secretable tmTNF [44]. Why, in our study, the expression of the
other NFκB-target genes studied did not exhibit expression changes
similar to that observed in IL6 remains unclear. However, it is
conceivable that the relative proportion of the effects of NFκB and
Erk1/2, and perhaps the effects of other factors not yet identiﬁed,
are involved in this regulation. Furthermore, the expression of TNF
and ΔpalTNF did not alter all aspects of TNFR1 signalling. Indeed,
we did not notice differences in Caspase 8 activation.
To integrate our results in the physiological context of TNF-producing
cells, onemust consider that at any time, tmTNF exists in two forms: one
that is non-palmitoylated, and another that is palmitoylated. Further-
more, these cells are permanently subjected to the effects of the sTNF
they produce. The non-palmitoylated form of TNF (outside lipid rafts)
would have no substantial effect on the biology of TNFR1, whereas the
palmitoylated form (inside lipid rafts) diminishes TNFR1 signalling by
interacting with the receptor and by reducing sTNF binding. The fact
that inhibition of palmitoylation in macrophages enhanced the binding
of endogenous sTNF to TNFR1 provides an evidence for the physiological
implication of this regulation. Therefore, our data introduce the new
concept that palmitoylation of TNF is a means by which TNF-producing
cells regulate their sensitivity to sTNF.
Supplementary data to this article can be found online at http://
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Fig. 7. Palmitoylation of TNF alters its interaction with TNFR1. (A) Lysates from control and stably TNF- and ΔpalTNF-expressing Hela cells were fractionated by sucrose density gradient
centrifugation and TNFR1wasmeasured by ELISA in each fraction. Inset positioned above the lipid raft fractions shows the % of TNF contained in those fractions (a— signiﬁcant versus control
and TNF-expressing cells (p=0.0036)). (B) Lipid raft and non-raft fractionswerepooled and concentrated, and TNFR1, caveolin-1 (cav) andADAM17were detected by immunoblot analysis.
Hela cells transfectedwith TNFR1 alone (c) or togetherwith Flag-tagged TNF orΔpalTNFwere lysedwith TritonX 100 buffer (C) or treatedwithDTBP to crosslink theproteins and lysedwith
RIPA buffer (D). Then, TNF was immunoprecipitated with anti-Flag antibody (IP:ﬂag) and TNFR1 was detected by immunoblot analyses. Mature and pro-forms of ADAM17 are indicated by
the black and white arrowheads, respectively. Arrow indicates TNFR1 position.
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